222 related articles for article (PubMed ID: 28051798)
1. Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key.
Norero B; Serrano CA; Sanchez-Fueyo A; Duarte I; Torres J; Ocquetau M; Barrera F; Arrese M; Soza A; Benítez C
Ann Hepatol; 2017 Jan-Feb 2017; 16(1):94-106. PubMed ID: 28051798
[TBL] [Abstract][Full Text] [Related]
2. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
3. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
6. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
8. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
9. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
10. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
[TBL] [Abstract][Full Text] [Related]
11. Conversion From Cyclosporine to Once-Daily Tacrolimus on 50:1 mg Basis: A Short-Term Pilot Study.
Shimada H; Uchida J; Kosoku A; Iwai T; Kabei K; Nishide S; Naganuma T; Kumada N; Takemoto Y; Nakatani T
Exp Clin Transplant; 2020 Feb; 18(1):1-7. PubMed ID: 31180299
[TBL] [Abstract][Full Text] [Related]
12. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
Gaston RS; Kaplan B; Shah T; Cibrik D; Shaw LM; Angelis M; Mulgaonkar S; Meier-Kriesche HU; Patel D; Bloom RD
Am J Transplant; 2009 Jul; 9(7):1607-19. PubMed ID: 19459794
[TBL] [Abstract][Full Text] [Related]
13. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
Gustafsson F; Andreassen AK; Andersson B; Eiskjær H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
[TBL] [Abstract][Full Text] [Related]
15. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
[TBL] [Abstract][Full Text] [Related]
16. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
18. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients.
Mourer JS; de Koning EJ; van Zwet EW; Mallat MJ; Rabelink TJ; de Fijter JW
Transplantation; 2013 Jul; 96(1):49-57. PubMed ID: 23715049
[TBL] [Abstract][Full Text] [Related]
19. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H; Pascual J; Viklicky O; Basic-Jukic N; Cassuto E; Kim DY; Cruzado JM; Sommerer C; Adel Bakr M; Garcia VD; Uyen HD; Russ G; Soo Kim M; Kuypers D; Buchler M; Citterio F; Hernandez Gutierrez MP; Bernhardt P; Chadban S;
Transplantation; 2019 Sep; 103(9):1953-1963. PubMed ID: 30801548
[TBL] [Abstract][Full Text] [Related]
20. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
